5/15
03:19 pm
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $60.00 price target on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $60.00 price target on the stock.
5/9
05:55 pm
advm
Adverum Biotechnologies: Q1 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Adverum Biotechnologies: Q1 Earnings Snapshot [Yahoo! Finance]
5/9
04:12 pm
advm
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights [Yahoo! Finance]
Low
Report
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights [Yahoo! Finance]
5/9
04:05 pm
advm
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
Medium
Report
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
5/3
08:00 am
advm
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
Medium
Report
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
5/2
11:44 am
advm
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]
Medium
Report
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]
5/1
11:02 pm
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
4/30
07:15 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
4/29
08:03 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Mizuho from $40.00 to $22.00. They now have a "buy" rating on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Mizuho from $40.00 to $22.00. They now have a "buy" rating on the stock.
4/25
04:08 pm
advm
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting [Yahoo! Finance]
Low
Report
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting [Yahoo! Finance]
4/25
04:05 pm
advm
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
Low
Report
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
4/23
11:08 am
advm
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]
Medium
Report
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]
4/4
05:39 pm
advm
Gene Therapies in Ophthalmology Market to Register Immense Growth at a CAGR of 57.8% by 2034 | DelveInsight [Yahoo! Finance]
Medium
Report
Gene Therapies in Ophthalmology Market to Register Immense Growth at a CAGR of 57.8% by 2034 | DelveInsight [Yahoo! Finance]
4/4
11:39 am
advm
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? [Yahoo! Finance]
Medium
Report
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? [Yahoo! Finance]
3/27
11:20 am
advm
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) [Yahoo! Finance]
Low
Report
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) [Yahoo! Finance]
3/22
02:04 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/19
02:24 pm
advm
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies [Yahoo! Finance]
Low
Report
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies [Yahoo! Finance]
3/19
11:00 am
advm
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Medium
Report
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
3/19
09:00 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
3/19
08:37 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $3.00 to $2.00. They now have a "sector perform" rating on the stock.
Medium
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $3.00 to $2.00. They now have a "sector perform" rating on the stock.
3/18
04:20 pm
advm
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates [Yahoo! Finance]
Medium
Report
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates [Yahoo! Finance]
3/18
04:05 pm
advm
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
Medium
Report
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
3/14
02:03 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/6
11:04 pm
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/28
04:05 pm
advm
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
Medium
Report
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference